- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - AstraZeneca PLC - H1 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 5
AnnouncementREG - AstraZeneca PLC - AstraZeneca PLC - H1 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 4
AnnouncementREG - AstraZeneca PLC - AstraZeneca PLC - H1 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 3
AnnouncementREG - AstraZeneca PLC - AstraZeneca PLC - H1 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 2
AnnouncementREG - AstraZeneca PLC - AstraZeneca PLC - H1 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 1
AnnouncementREG - AstraZeneca PLC - Faslodex receives EU approval for 1L breast cancer <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Total Voting Rights <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Faslodex CHMP positive opinion in 1L breast cancer <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZ agreement with Grünenthal for rights to Zomig <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - ASTRAZENECA PRICES A $2BN BOND ISSUE <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - LYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Total Voting Rights <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Directorate Change <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Bydureon EXSCEL trial meets T2D safety objective <Origin Href="QuoteRef">AZN.L</Origin>
Announcement